Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2008
10/30/2008WO2008088900A3 Polymorphic forms of rimonabant base and processes for preparation thereof
10/30/2008WO2008088727A3 Endothelin receptor antagonists
10/30/2008WO2008087491A8 Method for treating or preventing symptoms of hormonal variations
10/30/2008WO2008087461B1 Use of kynurenic acid and derivatives thereof in the treatment of conditions of the gastrointestinal tract accompanied by hypermotility and inflammation or gout or multiple sclerosis
10/30/2008WO2008087323A3 Galenic form for the transmucosal delivery of paracetamol
10/30/2008WO2008083252A3 Methods of use for cyclopamine analogs
10/30/2008WO2008083200A3 Spiroheterocyclic glycosides and methods of use
10/30/2008WO2008080601A3 Process for the preparation of loperamide
10/30/2008WO2008076949A3 Quinazoline derivatives and methods of treatment
10/30/2008WO2008076296A3 D-ribose for treating suboptimal pulmonary function
10/30/2008WO2008074752A3 Indolylmaleimide derivatives as kinase inhibitors
10/30/2008WO2008073457A3 Methods for determining prognoses and therapeutic interventions for ovarian carcinomas
10/30/2008WO2008073311A3 Substituted diazepine sulfonamides as bombesin receptor subtype-3 modulators
10/30/2008WO2008069972A3 Systems for effecting cessation of tobacco use
10/30/2008WO2008069921A3 Oral transmucosal nicotine dosage form
10/30/2008WO2008067177A3 Methods for the treatment of alcohol abuse, addiction and dependency
10/30/2008WO2008064320A3 Hydrindane analogs having sphingosine 1-phosphate receptor agonist activity
10/30/2008WO2008063768A3 Compositions and methods for treating metabolic diseases
10/30/2008WO2008063752A3 An enzyme regulating ether lipid signaling pathways
10/30/2008WO2008059368A3 Fused 2-amino pyrimidine compounds and their use for the treatment of cancer
10/30/2008WO2008057497A3 Small organic molecule regulators of cell proliferation
10/30/2008WO2008056377A3 Polymorphic forms of rimonabant
10/30/2008WO2008056264A3 Novel nucleotide analogues as percursor molecules for antivirals
10/30/2008WO2008055940A3 Combination therapy with sglt-2 inhibitors and their pharmaceutical compositions
10/30/2008WO2008052126A3 Ointment comprising phosphatidylserine as active agent for cancer treatment
10/30/2008WO2008051416A3 Compounds that inhibit the activity of hsp90 for treating infections
10/30/2008WO2008049657A3 Use of (meth)acrylate copolymers in slow-release pharmaceutical forms for reducing the influence of ethanol on active ingredient release
10/30/2008WO2008046860A3 Bioavailable combinations for hcv treatment
10/30/2008WO2008039644A3 Compositions and methods for treating cancer
10/30/2008WO2008036678A3 Combination comprising a peroxisome proliferator activated receptor agent and a second neurogenic agent for treating a nervous system disorder, increasing neurodifferentiation and increasing neurogenesis
10/30/2008WO2008036239A3 Use of lxr agonists for the treatment of osteoarthritis
10/30/2008WO2008034122A3 Hindered ester-based biodegradable linkers for oligonucleotide delivery
10/30/2008WO2008033440A3 Treatment of hyperproliferative diseases with anthraquinones
10/30/2008WO2008030408A3 Proteomimetic compounds as inhibitors of the interaction of a nuclear receptor with coactivator peptides
10/30/2008WO2008030217A3 Methods of reducing risk of infection from pathogens with soluble amide and ester pyrazinoylguanidine sodium channel blockers
10/30/2008WO2008027547A3 Antioxidant therapies
10/30/2008WO2008027341A3 Topical ophthalmic formulations
10/30/2008WO2008024844A3 Anticancer combination therapies
10/30/2008WO2008024843A3 Combination therapy method for treating hepatitis c virus infection and pharmaceutical compositions for use therein
10/30/2008WO2008024759A3 Immunomodulatory compounds that target and inhibit the py+3 binding site of tyrosene kinase p56 lck sh2 domain
10/30/2008WO2008022784A3 Long-lasting absorption of flavonoids
10/30/2008WO2008022204A3 Thiourea compounds
10/30/2008WO2008021049A9 Crystalline antifungal compounds
10/30/2008WO2008021049A2 Crystalline antifungal compounds
10/30/2008WO2008016648A3 Certain chemical entities, compositions and methods
10/30/2008WO2008015577A3 Sensizitation of cancer cells to therapy using sina targeting genes from the 1p and 19q chromosomal regions
10/30/2008WO2008013987A3 N-alkyl substituted piperazinylmethylquinazolinones and azepanylmethylquinazolinones
10/30/2008WO2008013928A3 Treatment of cancer with interferon gene delivery in combination with a tgf-beta inhibitor
10/30/2008WO2008011074A3 Histone deacetylase inhibitors
10/30/2008WO2008011017A3 Methods and compositions for treating vascular disease
10/30/2008WO2008008397A3 Fatty acid pharmaceutical foam
10/30/2008WO2008006007A3 Defective cystic fibrosis transduction regulator (cftr) causes increased sphingolipid synthesis
10/30/2008WO2008005542A3 Antiviral phosphinate compounds
10/30/2008WO2008005471A3 Novel heterobicyclic compounds
10/30/2008WO2007149500A3 Formulations containing hybrid dendrimers
10/30/2008WO2007147104A3 Novel compounds
10/30/2008WO2007146835A3 Indenoisoquinoline-releasable polymer conjugates
10/30/2008WO2007146761A3 Diaryl pyrimidinones and related compounds
10/30/2008WO2007127603A3 Apparatus and methods for pain relief using ultrasound energized polymers
10/30/2008WO2007127293A3 Novel streptomyces-derived antimicrobial compound and method of using same against antibiotic-resistant bacteria
10/30/2008WO2007126362A8 Compounds that are agonists of muscarinic receptors and that may be effective in treating pain, alzheimer's disease and/or schizophrenia
10/30/2008WO2007126136A3 Mask- tasting solid preparation of pioglitazone
10/30/2008WO2007124476A3 Ophthalmic and related aqueous solutions containing antifungal agents, uses therefor and methods for preparing them
10/30/2008WO2007121432A3 Benzoazepin-oxy-acetic acid derivatives as ppar-delta agonists used for the increase of hdl-c, lower ldl-c and lower cholesterol
10/30/2008WO2007118226A3 Anthracenedione compounds
10/30/2008WO2007114926A3 Kinase antagonists
10/30/2008WO2007112043A3 Synthetic pentacyclic triterpenoids and derivatives of betulinic acid and betulin
10/30/2008WO2007109180A3 Stabilized, sterilized collagen scaffolds with active adjuncts attached
10/30/2008WO2007106439A3 Homotropanes with central nervous system activity
10/30/2008WO2007100610A3 Pyridine, pyrimidine and pyrazine derivatives as cxcr3 receptor modulators
10/30/2008WO2007098205A3 Cocoa products and methods of treating cardiovascular conditions with sugar-free cocoa
10/30/2008WO2007070598A3 Nucleotide and oligonucleotide prodrugs
10/30/2008WO2007070598A2 Nucleotide and oligonucleotide prodrugs
10/30/2008WO2007017768A3 Novel uses for drugs targeting glutamine synthetase
10/30/2008WO2007011886A3 Treatment with azetidinone-based cholesterol absorption inhibitors and omega-3 fatty acids and a combination product thereof
10/30/2008WO2006128129A3 Method for treating cancer
10/30/2008WO2006073950A3 Nanoparticles for protein drug delivery
10/30/2008WO2006053172A3 The use of estriol and other estranes, estrogens and estrogen receptor active compositions in the treatment of psoriasis and other autoimmune diseases
10/30/2008WO2005021596A3 Compositions and methods for glycogen synthesis
10/30/2008US20080271167 for treatment of viral infection and nervous systtem disorders
10/30/2008US20080269875 Coating for a Medical Device Having an Anti-Thrombotic Conjugate
10/30/2008US20080269511 Antitumor agents; synthetic derivatives equivalent to marine polyketide derived components isolated from bryozoan Myriapora truncata
10/30/2008US20080269488 Characterized by x-ray reflections at 8.4 degrees, 10.8 degrees, 20.0 degrees, 20.4 degrees, and 21.2 degrees +-0.2 degrees 2 theta.
10/30/2008US20080269487 6-{[1-(carbamoylmethyl)piperidin-4-yl]oxy}-4-(3-chloro-2-fluoroanilino)-7-methoxyquinazoline; prevent, treat tumours which are sensitive to inhibition of erbB receptor tyrosine kinases
10/30/2008US20080269481 N-heterocyclyl- or cycloalkyl-N-(2-carboxy-5-aryl-3-thiophenyl)cycloalkanecarboxamides, e.g., 5-(3-fluorophenyl)-3-[isopropyl-(4-methylcyclohexanecarbonyl)amino]-thiophene-2-carboxylic acid; especially for prevention and treatment of HVC
10/30/2008US20080269351 Alkylated hydroxyaromatic compound substantially free of endocrine disruptive chemicals and method of making the same
10/30/2008US20080269350 St104p, an anti-angiogenic agent
10/30/2008US20080269349 administering an isolated astaxanthin and a mono- or di-ester thereof; controlling cytokine or TGF- alpha -related gene expression; reducing muscle atrophy, treating diabetes
10/30/2008US20080269348 Novel Arylbicyclo[3.1.0]Hexylamines And Methods And Compositions For Their Preparation And Use
10/30/2008US20080269347 injectable pharmaceutical composition also including EDTA, antioxidant, selected from cysteine, citric acid, thioglycerol, acetylcysteine; treating anaphylaxis, asthma, or cardiac arrest; stable in light, oxygen, and/or heat conditions without a stabilizer
10/30/2008US20080269346 B-Blocker Pharmacogenetics in Heart Failure
10/30/2008US20080269345 Quarternary Ammonium Compound, Process for Producing the Same, Therapeutic Agent for Cerebrovascular Disorder, and Therapeutic Agent for Heart Disease
10/30/2008US20080269344 respiratory diseases such as asthma, chronic obstructive pulmonary disease, bronchitis; useful in the treatment of nervous system injury and premature labor; 1-{2-[N-2-(4-hydroxy-3-formylaminophenyl)-2-(RS) hydroxyethyl]aminoethyl}-4-[N-(2-phenyl-2-(RS)-hydroxyethyl)amino]phenyl; milveterol
10/30/2008US20080269343 Galenic formulations of organic compounds
10/30/2008US20080269342 Pleuromutilin Derivatives and Its Use
10/30/2008US20080269341 administering to patient fenretinide for treating an infectious disease, or bone disease osteopenia or osteoporosis; decreasing arachidonic acid levels, increasing docosahexaenoic acid; for increase osteoblast formation; diagnostic and screening disease based on the lipid level
10/30/2008US20080269340 BIS (thio-hydrazide amide) salts for treatment of cancers
10/30/2008US20080269339 antiinflammatory mixture for treating chronic inflammatory skin disease, not limited to psoriasis; Calcipotriol, Valproic acid, or suberolyanilide hydroxamic acid and ZD1839 (iressa, gefitinib), PD153035, or SU 5271; synergistic effect
10/30/2008US20080269338 Aqueous solutions containing chloramine which are free from di-and trichloroamine, as well as from ammonia
10/30/2008US20080269336 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
1 ... 3017 3018 3019 3020 3021 3022 3023 3024 3025 3026 3027 3028 3029 3030 3031 3032 3033 3034 3035 3036 3037 ... 7860